WO2008015535A3 - Composition with improved antioxidant and antiglycating activity - Google Patents

Composition with improved antioxidant and antiglycating activity Download PDF

Info

Publication number
WO2008015535A3
WO2008015535A3 PCT/IB2007/002186 IB2007002186W WO2008015535A3 WO 2008015535 A3 WO2008015535 A3 WO 2008015535A3 IB 2007002186 W IB2007002186 W IB 2007002186W WO 2008015535 A3 WO2008015535 A3 WO 2008015535A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
effective amount
compositions
antiglycating
activity
Prior art date
Application number
PCT/IB2007/002186
Other languages
French (fr)
Other versions
WO2008015535A2 (en
Inventor
Pierluigi Guasti
Original Assignee
Difass S A
Pierluigi Guasti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Difass S A, Pierluigi Guasti filed Critical Difass S A
Publication of WO2008015535A2 publication Critical patent/WO2008015535A2/en
Publication of WO2008015535A3 publication Critical patent/WO2008015535A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

In a first aspect, the present invention refers to a composition for human use comprising at least an effective amount of α-lipoic acid and at least an effective amount of carnosine per daily dosage amount. In a second aspect, the present invention refers to a composition for human use comprising at least an effective amount of zinc and at least an effective amount of carnosine per daily dosage amount. In other aspects, the present invention also refers to a composition for oral use comprising one of said compositions and to a kit comprising a) a liquid phase which is acceptable from the nutritional standpoint, and b) a powder phase, wherein said liquid phase or said powder phase comprise said compositions. Advantageously, such compositions allow to attain an unexpected increase of the antioxidant and antiglycating activity, without inducing undesired side effects, in particular to prevent and/or to reduce the risk of onset, as well as to reduce the impact and/or to assist the treatment of the chronic complications of diabetes.
PCT/IB2007/002186 2006-08-01 2007-07-27 Composition with improved antioxidant and antiglycating activity WO2008015535A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2006A001522 2006-08-01
IT001522A ITMI20061522A1 (en) 2006-08-01 2006-08-01 COMPOSITION OF ANTI-OXIDANT AND IMPROVED ANTICLICANT

Publications (2)

Publication Number Publication Date
WO2008015535A2 WO2008015535A2 (en) 2008-02-07
WO2008015535A3 true WO2008015535A3 (en) 2008-04-17

Family

ID=38938282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002186 WO2008015535A2 (en) 2006-08-01 2007-07-27 Composition with improved antioxidant and antiglycating activity

Country Status (2)

Country Link
IT (1) ITMI20061522A1 (en)
WO (1) WO2008015535A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20090073A1 (en) * 2009-04-08 2010-10-09 Difass S A LONG TERM ALFA-LIPOIC ACID.
IT1398282B1 (en) * 2009-07-30 2013-02-22 Difass S A Ora Farmapros S P A COMPOSITION INCLUDING ALPHA-LIPOIC ACID AND CARNOSINE FOR THE TREATMENT OF THE GHOST ARTHUS SYNDROME
CA2779518A1 (en) * 2009-11-01 2011-05-05 Synthetic Biologics, Inc. Gastroretentive oral high dose zinc preparations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004690A1 (en) * 1991-09-09 1993-03-18 Peptide Technology Limited Method for the treatment of the complications and pathology of diabetes
US20050085454A1 (en) * 2003-10-16 2005-04-21 Natreon Inc. Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
WO2005117827A1 (en) * 2004-05-28 2005-12-15 Laboratoires Expanscience Use of furan alkyls for a cellulite cosmetic treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004690A1 (en) * 1991-09-09 1993-03-18 Peptide Technology Limited Method for the treatment of the complications and pathology of diabetes
US20050085454A1 (en) * 2003-10-16 2005-04-21 Natreon Inc. Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
WO2005117827A1 (en) * 2004-05-28 2005-12-15 Laboratoires Expanscience Use of furan alkyls for a cellulite cosmetic treatment

Also Published As

Publication number Publication date
WO2008015535A2 (en) 2008-02-07
ITMI20061522A1 (en) 2008-02-02

Similar Documents

Publication Publication Date Title
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2009027820A3 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008039431A3 (en) Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
WO2008116129A3 (en) Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
IL195030A (en) Dpp iv inhibitor formulations
WO2010028132A3 (en) Novel choline cocrystal of epalrestat
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2008097640A3 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007108990A3 (en) Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2011090270A3 (en) Composition containing osmotin for preventing and treating neurological disorders
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2006068796A3 (en) Inhibitors of akt activity
WO2005102296A3 (en) Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
WO2010011926A3 (en) A novel betaine cocrystal of epalrestat

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07804676

Country of ref document: EP

Kind code of ref document: A2